Palliative Strahlentherapie

Zusammenfassung

Die meisten Tumorpatienten erhalten im Verlauf ihrer Erkrankung eine Strahlentherapie. Zwischen 30 und 50 % aller Strahlenbehandlungen werden unter palliativer Zielsetzung durchgeführt. Durch eine lokale Bestrahlung können vielfältige tumorbedingte Symptome gelindert oder präventiv zukünftig bedrohliche Situationen durch den Tumor oder durch Metastasen abgewendet werden. Die Strahlentherapie ist eine lokal wirksame Therapie und erzeugt typischerweise keine systemischen und i. d. R. nur milde Nebenwirkungen. Der folgende Beitrag gibt einen Überblick über Prinzipien und neue Entwicklungen in der palliativen Strahlentherapie.

Abstract

The majority of cancer patients will require radiation therapy at some times during the course of their disease. An estimated 30–50 % of all radiation treatments are of palliative nature, either to alleviate symptoms or prophylactic to prevent deterioration of quality of live due to local progressive disease. Radiotherapy is a locally effective tool and typically causes no systemic and mostly mild acute side effects. The following article will provide an overview of principles and new developments in palliative radiation therapy.

Literatur

• 1 Lutz T, Chow L, Hartsell W. et al . A review of hypofractionated palliative radiotherapy.  Cancer. 2007;  109 1463-1469
• 2 Christakis N A, Lamont E B. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study.  BMJ. 2000;  320 469-472
• 3 Glare P, Virik K, Jones M. et al . A systematic review of physicians' survival predictions in terminally ill cancer patients. Review.  BMJ. 2003;  327 195-198
• 4 Gripp S, Moeller S, Bölke E. et al . Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression.  J Clin Oncol. 2007;  25 3313-3320
• 5 Maltoni M, Caraceni A, Brunelli C. et al . Prognostic factors in advanced cancer patients: evidence-based clinical recommendations – a study by the Steering Committee of the European Association for Palliative Care.  J Clin Oncol. 2005;  23 6240-6248
• 6 Glare P A, Sinclair C T. Palliative medicine review: prognostication. Review.  J Palliat Med. 2008;  11 84-103
• 7 Van der Linden Y M, Dijkstra S P, Vonk E J. et al . Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy.  Cancer. 2005;  103 320-328
• 8 Nieder C, Nestle U, Motaref B. et al . Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?.  Int J Radiat Oncol Biol Phys. 2000;  46 297-302
• 9 Rades D, Dunst J, Schild S E. A new scoring system to predict the survival of patients treated with whole-brain radiotherapy for brain metastases.  Strahlenther Onkol. 2008;  184 251-255
• 10 Sperduto P W, Berkey B, Gaspar L E. et al . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.  Int J Radiat Oncol Biol Phys. 2008;  70 510-514
• 11 Rades D, Rudat V, Veninga T. et al . A score predicting posttreatment ambulatory status in patients irradiated for metastatic spinal cord compression.  Int J Radiat Oncol Biol Phys. 2008;  72 905-908 , Epub 2008 Apr 23
• 12 Chow E, Abdolell M, Panzarella T. et al . Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic.  Int J Radiat Oncol Biol Phys. 2009;  73 280-287
• 13 Shakespeare T P, Lu J J, Back M F. et al . Patient preference for radiotherapy fractionation schedule in the palliation of painful bone metastases.  J Clin Oncol. 2003;  21 2156-2162
• 14 Tang J I, Shakespeare T P, Lu J J. et al . Patients' preference for radiotherapy fractionation schedule in the palliation of symptomatic unresectable lung cancerdagger.  J Med Imaging Radiat Oncol. 2008;  52 497-502
• 15 Gaspar L, Scott C, Rotman M. et al . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.  Int J Radiat Oncol Biol Phys. 1997;  37 745-751
• 16 Hoskin P J. Bisphosphonates and radiation therapy for palliation of metastatic bone disease.  Cancer Treat Rev. 2003;  29 321-327
• 17 Vassiliou V, Kardamakis D, Kalogeropoulou C. Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.  J Surg Oncol. 2008;  98 567-568
• 18 Wu J S, Wong R, Johnston M. et al . Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.  Int J Radiat Oncol Biol Phys. 2003;  55 594-605
• 19 Wai M S, Mike S, Ines H. et al . Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy – a systematic review of the randomized trials.  The Cochrane database of systematic reviews. 2004;  ((2)) , CD004721
• 20 van der Linden Y M, Lok J J, Steenland E. et al . Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment.  Int J Radiat Oncol Biol Phys. 2004;  59 528-537
• 21 Koswig S, Budach V. Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10-mal 3 Gy vs. 1-mal 8 Gy).  Strahlenther Onkol. 1999;  175 500-508
• 22 Tang V, Harvey D, Park Dorsay J. et al . Prognostic indicators in metastatic spinal cord compression: using functional independence measure and Tokuhashi scale to optimize rehabilitation planning.  Spinal Cord. 2007;  45 671-677
• 23 Helweg-Larsen S, Sørensen P S, Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients.  Int J Radiat Oncol Biol Phys. 2000;  46 1163-1169
• 24 Rades D, Heidenreich F, Karstens J H. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression.  Int J Radiat Oncol Biol Phys. 2002;  53 975-979
• 25 Patchell R A, Tibbs P A, Regine W F. et al . Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.  Lancet. 2005;  366 643-648
• 26 Rades D, Stalpers L J, Hulshof M C. et al . Comparison of 1 × 8 Gy and 10 × 3 Gy for functional outcome in patients with metastatic spinal cord compression.  Int J Radiat Oncol Biol Phys. 2005;  62 514-518
• 27 Katagiri H, Takahashi M, Wakai K. et al . Prognostic factors and a scoring system for patients with skeletal metastasis.  J Bone Joint Surg Br. 2005;  87 698-703
• 28 Rades D, Lange M, Veninga T. et al . Preliminary results of spinal cord compression recurrence evaluation (score-1) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression.  Int J Radiat Oncol Biol Phys. 2009;  73 228-234 , Epub 2008 Jun 6
• 29 Guckenberger M, Goebel J, Wilbert J. et al . Clinical outcome of dose-escalated image-guided radiotherapy for spinal metastasis.  Int J Radiat Oncol Biol Phys. 2009 in press; 
• 30 Spanos W J, Clery M, Perez C A. et al . Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502).  Int J Radiat Oncol Biol Phys. 1994;  29 961-967
• 31 Janjan N A. Palliative therapy. Introduction.  Semin Radiat Oncol. 2000;  10 169-174
• 32 Porceddu S V, Rosser B, Burmeister B H. et al . Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment – „Hypo Trial”.  Radiother Oncol. 2007;  85 456-462
• 33 Agarwal J P, Nemade B, Murthy V. et al . Hypofractionated, palliative radiotherapy for advanced head and neck cancer.  Radiother Oncol. 2008;  89 51-56
• 34 Falk S J, Girling D J, White R J. et al . Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. Medical Research Council Lung Cancer Working Party.  BMJ. 2002;  325 465
• 35 Fairchild A, Harris K, Barnes E. et al . Palliative thoracic radiotherapy for lung cancer: a systematic review.  J Clin Oncol. 2008;  26 4001-4011
• 36 Budach W, Belka C. Palliative percutaneous radiotherapy in non-small-cell lung cancer.  Lung Cancer. 2004;  45 (Suppl. 2) 239-245
• 37 Toy E, Macbeth F, Coles B. et al . Palliative thoracic radiotherapy for non-small-cell lung cancer: a systematic review.  Am J Clin Oncol. 2003;  26 112-120
• 38 Kramer G W, Wanders S L, Noordijk E M. et al . Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer.  J Clin Oncol. 2005;  23 2962-2970
• 39 Kramer G W, Gans S, Ullmann E. et al . Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment?.  Int J Radiat Oncol Biol Phys. 2004;  58 1388-1393
• 40 Wong W W, Schild S E, Sawyer T E. et al . Analysis of outcome in patients reirradiated for brain metastases.  Int J Radiat Oncol Biol Phys. 1996;  34 585-590
• 41 Kao J, Garofalo M C, Milano M T. et al . Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.  Cancer Treat Rev. 2003;  29 21-30
• 42 Flentje M, Frey M, Kuttig H. et al . Radiotherapy of locally recurring colorectal tumors. Prognostic factors, follow-up diagnosis and results.  Strahlenther Onkol. 1988;  164 402-407
• 43 Overgaard M, Overgaard J, Sell A. Dose-response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer.  Radiother Oncol. 1984;  1 217-225
• 44 Rödel C, Grabenbauer G G, Schick C. et al . Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer.  Strahlenther Onkol. 2000;  176 161-167